Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bevacizumab combined with docetaxel and cisplatin as first-line treatment for metastatic or locally advanced non-small cell lung cancer
2006-005619-88Phase 2Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Roche Farma, S.A. Primary endpoints: Progression-free survival, Objective response rate and 4 more. Started Mar 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-005619-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005619-88.